PMID- 28993188
OWN - NLM
STAT- MEDLINE
DCOM- 20180706
LR  - 20180706
IS  - 1879-1166 (Electronic)
IS  - 0198-8859 (Linking)
VI  - 78
IP  - 11-12
DP  - 2017 Nov
TI  - The effect of killer cell immunoglobulin-like receptor genotype on outcome of 
      hematopoietic stem cell transplantation from matched sibling.
PG  - 684-691
LID - S0198-8859(17)30513-X [pii]
LID - 10.1016/j.humimm.2017.10.004 [doi]
AB  - The alloreactivity of natural killer (NK) cell after allogeneic hematopoietic 
      stem cell transplantation (AHSCT) is regulated by the interaction between donor 
      killer immunoglobulin-like receptors (KIRs) and recipient human leukocyte antigen 
      (HLA)-class I molecules. The aim was to identify KIR genes, haplotypes and their 
      HLA-class I ligands and to investigate their association with transplantation 
      outcome. The study included 65 patient/donor pairs who received AHSCT from 
      HLA-matched identical siblings. KIR genotyping was done for donors using reverse 
      sequence specific oligonucleotide probes (rSSO) coupled with luminex technology, 
      while HLA-C genotyping was performed in patients using rSSO strip assay. In 
      multivariate analysis, KIR2DS4 was associated with significant reduced incidence 
      of relapse (p = .002). A trend towards reduced incidence of relapse was also 
      observed with more than two KIR B motifs (p = .09), whereas a significant 
      increased relapse was associated with homozygous HLA-C2 ligand compared to 
      combined C1/C2 and C1/C1 (p = .04). Activating KIR2DS3 was associated with rapid 
      leukocyte engraftment (p = .02). While, KIR 2DL5 was associated with decreased 
      CMV infection (p = .03) and better platelets engraftment (p = .05). KIR genes, 
      haplotypes and HLA-C alleles have an impact on HSCT outcome. Better selection of 
      donors with favorable KIR genotype can improve HLA-matched sibling HSCT outcome 
      especially for AML patients.
CI  - Copyright (c) 2017 American Society for Histocompatibility and Immunogenetics. 
      Published by Elsevier Inc. All rights reserved.
FAU - Elfishawi, Sally M
AU  - Elfishawi SM
AD  - Bone Marrow Transplantation Laboratory Unit, National Cancer Institute, Cairo 
      University, Egypt.
FAU - Mossallam, Ghada I
AU  - Mossallam GI
AD  - Bone Marrow Transplantation Laboratory Unit, National Cancer Institute, Cairo 
      University, Egypt. Electronic address: ghada.mossallam@nci.cu.edu.eg.
FAU - El-Fattah, Raafat Abd
AU  - El-Fattah RA
AD  - Department of Medical Oncology, National Cancer Institute, Cairo University, 
      Egypt.
FAU - El-Haddad, Alaa
AU  - El-Haddad A
AD  - Department of Pediatric Oncology, National Cancer Institute, Cairo University, 
      Egypt.
FAU - Kamel, Azza M
AU  - Kamel AM
AD  - Bone Marrow Transplantation Laboratory Unit, National Cancer Institute, Cairo 
      University, Egypt.
LA  - eng
PT  - Journal Article
DEP - 20171007
PL  - United States
TA  - Hum Immunol
JT  - Human immunology
JID - 8010936
RN  - 0 (HLA-C Antigens)
RN  - 0 (KIR2DS3 protein, human)
RN  - 0 (KIR2DS4 protein, human)
RN  - 0 (Receptors, KIR)
RN  - 0 (Receptors, KIR2DL5)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Child
MH  - Female
MH  - Genotype
MH  - HLA-C Antigens/genetics
MH  - *Hematopoietic Stem Cell Transplantation
MH  - Histocompatibility
MH  - Histocompatibility Testing
MH  - Humans
MH  - Leukemia, Myeloid, Acute/*therapy
MH  - Male
MH  - Middle Aged
MH  - Polymorphism, Genetic
MH  - Receptors, KIR/*genetics
MH  - Receptors, KIR2DL5/*genetics
MH  - Siblings
MH  - Transplantation Tolerance
MH  - Young Adult
OTO - NOTNLM
OT  - Allogeneic hematopoietic stem cell transplantation
OT  - Killer immunoglobulin-like receptor
OT  - NK cell
OT  - Relapse
EDAT- 2017/10/11 06:00
MHDA- 2018/07/07 06:00
CRDT- 2017/10/11 06:00
PHST- 2016/12/02 00:00 [received]
PHST- 2017/07/25 00:00 [revised]
PHST- 2017/10/04 00:00 [accepted]
PHST- 2017/10/11 06:00 [pubmed]
PHST- 2018/07/07 06:00 [medline]
PHST- 2017/10/11 06:00 [entrez]
AID - S0198-8859(17)30513-X [pii]
AID - 10.1016/j.humimm.2017.10.004 [doi]
PST - ppublish
SO  - Hum Immunol. 2017 Nov;78(11-12):684-691. doi: 10.1016/j.humimm.2017.10.004. Epub 
      2017 Oct 7.